Voyager Therapeutics Alzheimer's Portfolio And ALPL NeuroShuttle Underscore Platform Momentum: Analyst [Yahoo! Finance]
Voyager Therapeutics, Inc. (VYGR)
Last voyager therapeutics, inc. earnings: 3/3 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.voyagertherapeutics.com
Company Research
Source: Yahoo! Finance
The management emphasized recent preclinical murine data from a head-to-head study showing that its alkaline phosphatase (ALPL) receptor-mediated non-viral NeuroShuttle sustained central nervous system (CNS) exposure for more than 3 weeks compared to less than 1 week with transferrin receptor shuttles, highlighting durability and a potential safety advantage In July, Voyager Therapeutic expanded its Alzheimer's disease (AD) franchise with the introduction of a wholly-owned program that modulates the expression of apolipoprotein E (APOE), the strongest genetic risk factor for Alzheimer's disease The program uses a proprietary intravenous (IV)-delivered, blood-brain barrier (BBB)-penetrant TRACER capsid to deliver a bifunctional payload that is designed to decrease expression of APOE in carriers of the variant APOE4, while delivering the variant APOE2. Analyst Patrick R. Trucchio views these updates as platform-enhancing and partner-catalyzing, and reiterates a Buy rating and a p
Show less
Read more
Impact Snapshot
Event Time:
VYGR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VYGR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VYGR alerts
High impacting Voyager Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VYGR
News
- Voyager Therapeutics (NASDAQ:VYGR) had its price target lowered by analysts at HC Wainwright from $30.00 to $25.00. They now have a "buy" rating on the stock.MarketBeat
- Voyager Therapeutics (NASDAQ:VYGR) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $8.00 price target on the stock.MarketBeat
- Voyager Reports Third Quarter 2025 Financial and Operating Results [Yahoo! Finance]Yahoo! Finance
- Transition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal Dementia [Yahoo! Finance]Yahoo! Finance
- Transition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal DementiaGlobeNewswire
VYGR
Earnings
- 11/10/25 - Beat
VYGR
Sec Filings
- 12/2/25 - Form EFFECT
- 12/1/25 - Form 424B3
- 11/14/25 - Form SCHEDULE
- VYGR's page on the SEC website